Back to Journals » International Medical Case Reports Journal » Volume 13

New-Onset Uveitis Possibly Caused by Secukinumab in a 47-Year-Old Male Patient with Long-Standing Ankylosing Spondylitis

Authors Nadwi H, Janaini M, Zammo M, Cheikh M, Almoallim H

Received 15 June 2020

Accepted for publication 24 July 2020

Published 5 August 2020 Volume 2020:13 Pages 331—334

DOI https://doi.org/10.2147/IMCRJ.S265812

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Ronald Prineas


Huda Nadwi,1 Murad Janaini,1 Mohammed Zammo,2 Mohamed Cheikh,2 Hani Almoallim1– 3

1Department of Medicine, College of Medicine, Umm Alqura University, Makkah, Saudi Arabia; 2Department of Medicine, Dr. Soliman Fakeeh Hospital, Jeddah, Saudi Arabia; 3Alzaidi Chair of Research in Rheumatic Diseases, Umm Alqura University, Makkah, Saudi Arabia

Correspondence: Hani Almoallim
Department of Medicine, College of Medicine, Umm Alqura University, P.O. Box 1821, Jeddah 21441, Saudi Arabia
Tel +966 505703935
Email hmmoallim@uqu.edu.sa

Abstract: Secukinumab, “an IL-17 antagonist”, is one of the biological agents used to treat active ankylosing spondylitis (AS). Although it has been proven that certain agents are linked with a paradoxical increase in uveitis, there are limited data on whether secukinumab has this effect or not. We report a case of a new-onset anterior uveitis after 6 months of starting secukinumab in a 47-year-old male, HLA-B27 positive AS patient. He had a long-standing history with the disease over 25 years. He was treated in the past with methotrexate then adalimumab and later on with etanercept. He had no history of uveitis during all of this time. The uveitis was mild and treated conventionally with local measures while secukinumab was maintained. After a close follow-up, the uveitis had completely resolved. Is this part of the original disease or a possible side effect from secukinumab?

Keywords: spondyloarthritis, iritis, IL-17A inhibitors, biologics, ankylosing spondylitis, uveitis, secukinumab

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]